VBI Vaccines Inc (VBIV)

[cheynew]

VBIV Hep B fireside chat this morning at 11 EST.

Virtual fireside chat with analyst Steven Seedhouse, Ph.D., to take place at 11:00 AM ET on December 8, 2020
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that members of the VBI leadership team will discuss the recent news and strategic outlook for the Company’s hepatitis B (HBV) portfolio with covering analyst, Steven Seedhouse, Ph.D., from Raymond James & Associates, Inc. during a fireside chat at 11:00 AM ET on Tuesday, December 8, 2020. The discussion will highlight the Company’s two HBV pipeline candidates: VBI’s 3-antigen prophylactic HBV vaccine candidate, licensed in Israel as Sci-B-Vac ® , and VBI-2601, a novel recombinant, immunotherapeutic candidate for the treatment of chronic HBV infection.

The fireside chat can be accessed live via the Events/Presentations page in the Investors section of the Company’s website, or by clicking this link:

https://raymondjames.zoom.us/webinar/register/WN_i-eY5EFpSAWiQwiAub42Rg .

A replay of the webcast will be archived on the Company’s website following the live conference call.